A Pilot Study of Acupuncture for the Treatment of Pain in Sickle Cell Disease

Locations

1 United States site

Age

8 to 22 Years

Genotypes

HbSS, HbSC

Phase

N/A

Study type

Interventional

Gender

All

Interventions

Other

Compensation

Unknown

About the study

Sickle cell disease (SCD) is the most common genetic disorder in the United States affecting
approximately 100,000 individuals primarily of African ancestry. Pain is the most common
complication of SCD. Currently, the mainstay therapy for pain in SCD is opioids. The CDC
recommends using non-opioid, non-pharmacologic therapies for pain. There is a growing body of
literature to support the use of various integrative therapies for pain.

Acupuncture therapy is a non-pharmacological Chinese medicine approach which has been used in
many non-SCD conditions associated with pain. Proposed study will test acceptability and
feasibility of use of acupuncture in SCD patients hospitalized for pain. It is hypothesized
that the use of acupuncture as an adjuvant therapy will be acceptable to SCD patients
admitted for pain control. Its impact on opioid use and circulating cytokines and
neuropeptides will also be determined.

participation requirements

– subjects with SCD (HbSS, HbSC, HbSβ0 thalassemia, HbSOArab)

– Admitted for management of pain at Children’s National.

– Ability to provide informed consent/assent

participation restrictions

– Inability to give informed consent/assent as determined by the investigators

– SCD related complications such as acute chest syndrome requiring supplemental oxygen,
fever with bacteremia or concern for serious infection ex. osteomyelitis Local -skin
infection or condition not feasible for acupuncture

– Pregnancy or lactation

Locations

  • Washington, District of Columbia, United States, Children's National Health System, 20010